The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...

In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...

Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...

EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA ...